Today Navamedic launches MyControl Support in Norway, a free-of-charge patient
support program in collaboration with Observia, following a successful launch in
Sweden. A new patient engagement & support program targeted towards people with
clinical obesity. Via a brand-new online platform, the program aims to aid and
inform patients with obesity.

Navamedic, a Nordic pharma company, specialized in the field of obesity and
Observia, French e-health company specialized in patient engagement and support
solutions are proud to further provide support for patients in great need.
"Launching a platform like this is by far one of the most ambitious and
innovative initiatives we have offered the health care system. This is
continuing our efforts in attempting to highlight the complexity surrounding
this disease and offering both health care professionals and patients a
treatment option complementing and strengthening a regular treatment protocol."
says Kathrine Gamborg Andreassen, CEO of Navamedic.

A 16-week empowerment program

Patients embark on a 16-week program, comprising lifestyle recommendations and
doctor- and patient-validated information via SMS. Participants also receive
articles on topics such as the causes, risks and benefits of long-term weight
loss as well as treatment option information.

In addition, patients are invited to take on daily challenges (going to bed
early, practicing physical activity, eating healthy) that instil healthy habits
and to progress across 10 levels of challenge. Any patient suffering from
obesity can enrol in the program.

The design and the interface of the platform have been conceived by Navamedic
and Observia to encourage patients every day and engage them to play an active
role in the management of their health.


Launch in Norway follows successful pilot in Sweden

The patient support program was first launched in Sweden in October 2020. After
first promising results, the decision was taken to further deploy the program in
Norway, where 23.1% of the population suffers from obesity.

Obesity is linked to increased incidence of many chronic diseases (type 2
diabetes, CVD, respiratory complications, etc.) which lead to increased
morbidity. In the past few decades, greater awareness around obesity and its
consequences and burden have fostered the creation of dedicated support actions
and prevention.

MyControl Support is one of them and aims to help patients improve their quality
of life.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO
kga@navamedic.com

Morgane Freudiger Marketing & Communication Director, Observia
morgane.freudiger@observia-group.com

About Navamedic
Navamedic ASA is a Nordic pharma company and a reliable supplier of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
medical needs of patients and consumers by leveraging its highly scalable market
access platform, leading category competence and local knowledge.

Navamedic is present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in Oslo,
Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more
information, please visit www.navamedic.com



About Observia
At Observia, we are a passionate pioneer healthTech company committed to help
drive the healthcare (r)evolution and improve patients' lives. We seamlessly
design, configure and deploy multi-channel patient engagement & support
solutions, driven by AI and grounded in behavioral science, that enhance patient
engagement and deliver measurable behavioral and clinical results.

We work with all the main healthcare stakeholders that have at heart to build
patient-centered initiatives that improve patients and carers' lives and ease
healthcare professional daily workload: industrials (Pharma, Biotech, MedTech),
healthcare facilities, HCPs, patients' organizations and payers. Based in Paris
since 2011 and present in China since 2018, Observia's solutions are deployed
across 20 countries and more than 40 medical specialities.